{"id":9626,"date":"2024-03-18T10:02:09","date_gmt":"2024-03-18T10:02:09","guid":{"rendered":"https:\/\/cobrca.org\/?page_id=9626"},"modified":"2024-03-18T10:04:56","modified_gmt":"2024-03-18T10:04:56","slug":"supporters-and-exhibitors-2","status":"publish","type":"page","link":"https:\/\/cobrca.org\/cobrca2024\/supporters-and-exhibitors-2\/","title":{"rendered":"Supporters and Exhibitors"},"content":{"rendered":"

Supporters and Exhibitors<\/h3>\n

CoBrCa would like to thank the supporters. It is with the support of the industry that CoBrCa can continue in its mission to promote research and education and to disseminate new knowledge
\nClick on the logo to find out more about the company!<\/strong><\/p>\n

Platinum Supporter<\/span><\/strong><\/h3>\n\n\n\n
\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Gold Supporter<\/span><\/strong><\/h3>\n\n\n\n
\"endomag\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Silver Supporter<\/span><\/strong><\/h3>\n\n\n\n
\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

Bronze Supporters<\/span><\/strong><\/h3>\n<\/div>\n

 <\/p>\n\n\n\n
\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

 <\/p>\n

Exhibitors<\/span><\/strong><\/h3>\n<\/div>\n
\n\n\n\n\n\n
\"\"<\/a><\/td>\n\"endomag\"<\/a><\/td>\n<\/tr>\n
\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n
Veracyte<\/strong> is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, our exclusive license to a best-in-class diagnostics instrument (the nCounter Analysis System) positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California.
\nFor more information, please visit www.veracyte.com <\/a>and follow the company on Twitter (@veracyte).<\/div>\n
\n
Exact Sciences<\/strong> is a leading, global cancer diagnostics company. From early detection to diagnosis and treatment guidance, the company is offering and further developing a suite of tests to enable personalised care at all stages of the disease. In early breast cancer, the Oncotype DX\u00ae test<\/a> is the only test validated to identify patients likely to benefit from chemotherapy.
\nFor more information, please visit https:\/\/www.exactsciences.com<\/a>.<\/div>\n
\n
GC AESTHETICS\u00ae<\/strong>
\nThe QUALITY <\/strong>you Expect
\nThe OPTIONS<\/strong> you Need
\nThe PEACE OF MIND<\/strong> you DemandGC Aesthetics\u00ae is an established global medical device company focused on Aesthetic, Revision and Reconstruction procedures<\/strong>. With more than 40 years of experience<\/strong>, surgeons and patients in more than 70 countries with systems in place to ensure the safety of our products through pre-clinical testing, clinical studies and excellent global post-market surveillance use GCA\u00ae.
\nGCA\u00ae is A Confident Choice for Life\u2122<\/strong> supported by a 10-year prospective and multi-centric clinical study and an average of 17 years of extended long-term high patient satisfaction data<\/strong>. We provide the most comprehensive implant portfolio in the industry with breast, face, body implants and skin expanders to give surgeons quality surgical options.
\nMuch more than a European manufacturer of high-quality implants<\/strong>, we are proud to support our surgeons and patients by integrating and developing solutions<\/strong> that are designed to support the best outcome for women\u00b4s breast enhancement journey.
\nA Confident Choice for Life\u2122<\/strong>
\nFor more information, please visit https:\/\/www.gcaesthetics.com\/<\/a><\/div>\n
\n
At Endomag<\/strong>, we believe everyone deserves a better standard of cancer care \u2013 that\u2019s why we design our unique magnetic technologies with both the clinician and patient in mind. Many leading hospitals across the world use our solutions to help breast cancer patients avoid surgery when it isn\u2019t needed, and experience better outcomes when it is.
\nOur Magseed\u00ae marker is a tiny, non-radioactive seed, ideal for accurately marking tumours and lymph nodes, while the Magtrace\u00ae lymphatic tracer is the world\u2019s first, long-lasting, non-radioactive dual tracer for lymphatic mapping. Paired with the Sentimag\u00ae localisation platform, they have now been widely proven across over 100 clinical studies, featuring more than 20,000 patients.
\nThe Sentimag\u00ae platform has already helped 450,000+ women worldwide to access more precise and less invasive breast cancer treatment. Are you ready to join the magnetic revolution?
\nFor more information, please visit visit www.endomag.com<\/a><\/div>\n
\n
About Gilead Sciences<\/strong>
\nGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
\nFor more information, please visit visit www.gilead.com<\/a><\/div>\n
\n
Daiichi Sankyo UK <\/strong>and AstraZeneca UK<\/strong>: Combining collective expertise to push the boundaries of what is possible in cancer care. Our collaboration is based on a shared commitment to support patients.<\/p>\n

The CoBrCa Conference 2024 is supported by the pharmaceutical industry through sponsorship and the purchase of exhibition space. Sponsoring companies have no influence or involvement in the preparation of this event.
\nUK\/ADC\/03\/24\/0021 | March 2024<\/span><\/i><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Supporters and Exhibitors CoBrCa would like to thank the supporters. It is with the support of the industry that CoBrCa can continue in its mission to [\u2026]<\/span><\/p>\n","protected":false},"author":12,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-9626","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/9626"}],"collection":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/comments?post=9626"}],"version-history":[{"count":3,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/9626\/revisions"}],"predecessor-version":[{"id":9631,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/9626\/revisions\/9631"}],"wp:attachment":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/media?parent=9626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}